Nome is the Operating System for Personalized Therapies™. Where traditional pharmaceutical infrastructure was built for mass-market drugs, Nome provides the coordination layer that rare disease programs require: AI-driven genomic assessment, regulatory navigation, researcher and manufacturer matching, and end-to-end program management — all in one platform. Nome serves as a tech-enabled service company sitting between the patient and the clinic. For a patient or family, Nome delivers a free therapy eligibility assessment in 1–2 weeks, followed by an execution-ready action plan. For clinicians and foundations, Nome functions as an intelligent scientific program manager — handling the orchestration complexity that has historically made personalized drug development inaccessible outside of elite academic medical centers. The platform is modality-agnostic, with current focus on antisense oligonucleotides and gene therapies. Nome also operates as a preclinical CRO, offering target design, toxicology studies, and pre-clinical manufacturing services for rare genetic diseases. Founded by Steven Ringel — a rare disease patient, former Sema4, GeneDx, and Tempus operator, and founder of the Kizuna Foundation (foundation to develop retinal gene therapies) — Nome emerged from stealth in October 2025 backed by Twelve Below, Refactor Capital, and Inflect Health.

Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout.

Ouroboros Medicines is a biotechnology company that specializes in immunology and focuses on treating long-term immune-mediated illnesses. The company addresses chronic immune-mediated conditions directly by integrating scientific knowledge, a proven history of progressing cell-depleting treatments through clinical trials, and a strong pipeline.

Tenvie Therapeutics is a biotechnology company founded to improve patients' lives with neurological, cardiometabolic, and ophthalmic diseases. The company is focused on developing small molecules targeting brain inflammation, metabolic dysfunction, and lysosomal issues, with a robust pipeline inherited from Denali Therapeutics. Tenvie is progressing a range of therapeutics aimed at addressing neurological, cardiometabolic, and ophthalmic conditions. Its collection of fully owned, highly brain-penetrant, and precisely designed peripherally restricted small molecules targets three main factors of disease: alleviating inflammation, correcting metabolic dysfunction, and rejuvenating lysosomal function.

Helicore Biopharma is at the forefront of developing cutting-edge treatments for obesity and related disorders.

Callio Therapeutics focuses on developing next-generation, multi-payload antibody-drug conjugates to maximize therapeutic benefits.

GondolaBio is a clinical-stage biopharmaceutical company focused on developing next-generation therapeutics for genetic diseases. Originally launched as BridgeBioX, a subsidiary of BridgeBio, GondolaBio secured $300M in private financing from external investors in 2024 and became an independent company within the BridgeBio ecosystem. The company aims to leverage cutting-edge biological research to create breakthrough medicines addressing high unmet needs across multiple therapeutic areas, including neurology, pulmonology, cardiology, nephrology, and endocrinology. Located on the Stanford Life Sciences campus, GondolaBio fosters a unique hybrid environment where top scientists from around the world collaborate with senior leadership and advisors, blending industry expertise with academic innovation.

Jupiter Endovascular is a medical technology start-up. Its mission is to cover the entire spectrum of cardiovascular illness, seeing compelling potential to reinvent treatments for millions of people.

nChroma Bio's integrated product engine allows for safe, accurate, and targeted in vivo administration, addressing major shortcomings of current genetic medicine techniques.

Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence to learn the language of life and transform how we treat disease. The company seeks to rethink the drug discovery and development process from end-to-end by bringing together leading talent across three core areas: machine learning research to better understand biology, expansive data generation to power new models, and robust therapeutic product development to treat disease. Xaira is headquartered in the San Francisco Bay Area.

City Therapeutics is a biopharmaceutical company focusing on engineering next-generation small-interfering RNAs (siRNAs) to enhance RNAi-based therapies. The company develops a pipeline of innovative RNAi therapeutics aimed at addressing various disease indications. City Therapeutics prioritizes improving and expanding RNAi technology to achieve better patient outcomes. The leadership team includes experienced scientists and industry professionals dedicated to advancing the field of RNA interference.

Seaport Therapeutics operates as a clinical stage biopharmaceutical company.

Mirador Therapeutics envisions precision medicine for immune-mediated inflammatory and fibrotic diseases.

Ambrosia Biosciences offers drug development services for small molecule-based therapies for obesity and other metabolic disorders.

K-Scale Labs is a robotic engineering company specializing in creating open-source humanoid robots.

Chai Discovery creates Chai-1, a multi-modal foundation model designed for predicting molecular structures relevant to drug discovery. The model facilitates the unified prediction of proteins, small molecules, and nucleic acids, and is available for free for commercial applications. By enabling accurate predictions without the need for multiple sequence alignments, Chai-1 advances the capabilities of molecular modeling in the life sciences.

KALM Therapeutics provides non-steroidical treatment for eczema and psoriasis.

Eyconis, Inc. is a privately held, pre-clinical stage biopharmaceutical company focused on transforming the ophthalmology treatment paradigm through the development, manufacture, and commercialization of novel, best-in-class therapeutics for eye diseases. The Company is advancing a pipeline of therapeutic candidates addressing areas of high unmet need including wet age-related macular degeneration (AMD). Eyconis is partnered with a syndicate of leading biopharma investors including Frazier Life Sciences, RA Capital Management, venBio Partners, and HealthQuest Capital. The Company is headquartered in Redwood City, California, including research & development laboratories with scientific and manufacturing team members.

Kailera Therapeutics is a clinical-stage biotechnology company that provides revolutionary therapies for treating obesity and related diseases.

Developing innovative therapeutics to materially improve the lives of patients. We strive to be transparent and open in our goals, plans, and progress.

Expedition Therapeutics is a biotechnology company that develops novel therapies for inflammatory and respiratory diseases. The company advances EXPD-101, an oral once-daily inhibitor of DPP1, which targets neutrophilic inflammation and is positioned for chronic obstructive pulmonary disease (COPD) and other neutrophil-driven indications. It pursues global clinical development of EXPD-101 while exploring expansion into bronchiectasis, neutrophilic asthma, and related conditions. The leadership team combines expertise in drug discovery, translational science, clinical development, and business strategy. Expedition Therapeutics operates a model that integrates in-licensing of external innovation with internally generated programs.

VisiRose offers an innovative approach to treating infectious keratitis and other eye diseases.

GEMMABio is a therapeutics company that supports the rare disease community.

Converge Bio is at the forefront of integrating Generative AI with biological data. Our mission is to empower biotech and pharmaceutical companies to discover and develop more effective drugs faster, utilizing the power of Large Language Models (LLMs) specifically trained on biological languages.

Alys Pharmaceuticals engages in immuno-dermatology services. The company is reshaping the treatment landscape through advanced scientific innovations and a strong research and development-focused multi-platform pipeline. Alys emerged as a result of the strategic aggregation of 6 asset-centric companies backed by Medicxi.

Timberlyne Therapeutics is a clinical-stage biopharmaceutical company that develops and commercializes revolutionary medicines for autoimmune illnesses. The company utilizes its team's experience in drug development to secure top-tier assets focused on promising targets, and implementing them in disease areas with considerable unmet needs.

Bambusa Therapeutics operates as biotechnology company, that focuses on developing bispecific antibodies.

Noded Ai is preparing yourself for that customer meeting is tough. Noded brings them all together using your notes history and gives you exactly what you needed , when you need it. So you’re always prepared and one step ahead.

Nura Health is a molecular diagnostics company whose mission is to advance women's health through the development and delivery of novel practice-changing non-invasive tests. We prioritize innovative, evidence-based diagnostic methods enhanced by AI & Machine Learning in order to improve clinical outcomes for complex and debilitating diseases such as endometriosis, infertility disorders, and genetic conditions that impact quality of life and longevity.

Trace Neuroscience is a biopharmaceutical company that aims to extend the promise of genetic medicine to patients with neurodegenerative illnesses.

Coeptis Therapeutics focuses on the development and acquisition of pharmaceutical products. Coeptis’ pipeline is evolving from the partnerships being created with multiple pharmaceutical companies currently. As these relationships unfold, the product pipeline will be updated accordingly.

Kivu Bioscience is a biotech company developing next-generation antibody-drug conjugates to deliver best-in-class therapeutics and focused on rapidly advancing next generation transformative assets.

Jade Biosciences is developing transformative therapies to redefine the standard of care for inflammation and immunology indications.

Navigator Medicines operate as a biotech company that leads the advancement of biologics for targeted immune regulation & restoration.

Newleos Therapeutics is a biotech startup dedicated to producing safer and more effective neuroscience medicines.

DeltaGen is an enterprise AI company transforming buyside M&A by automating 80% of manual workflows—eliminating inefficiencies and accelerating deal velocity for corporate development teams, private equity firms, and strategic acquirers. Unlike traditional AI tools that rely on manual prompting, DeltaGen’s no-prompt AI delivers highly accurate, deterministic insights with seamless integration.

Cradle is a cryonics company that develops and proves the feasibility of human organs and whole-body reversible cryopreservation. That aims to focus on pausing and restarting biological functions through freezing to prevent tissue damage in dead bodies.

Tern Therapeutics develops transformative, one-time genetic treatments for rare diseases.

Valora Therapeutics is a biotechnology company that provides engineering of chimeric antibodies .

Pranax is a software company currently based in Pinehurst, Texas, United States. It has been founded in 2023.

Olio Labs utilizes AI for combo therapeutics, optimizing and minimizing side effects through automated discovery of protein interactions.

About HAPPY POTATO - Perfect Fries ! The world's best Flavored French Fries ! Feel the Flavor with everyone's favorite French fries Products Flavoring Perfect Fries

EvolutionaryScale is a developer of biological artificial intelligence models for therapeutic design. The business predicts protein structures by combining biological data from DNA sequences, gene expression, and epigenetic states, allowing scientists to use massive language models to create RNA-based medicinal therapies.

Kincell Bio collaborates with cell therapy developers by using considerable scientific experience and industry understanding. Transparency, accountability, and accuracy are essential to what makes us a reliable partner for process and analytical development, CMC assistance, and high-quality clinical cell therapy manufacturing services.

Founded in 2023 by a team of internationally recognized healthcare leaders, GalenusRx is revolutionizing medication safety with the power of precision. The company’s proprietary platform, APPRAISE, analyzes drug-drug, multi-drug, drug-gene, and drug-disease interactions to provide a unique and comprehensive risk assessment, individualized down to the DNA. Through the Lifesaving InsightsTM consulting service, Precision Clinical Pharmacists deliver tailored recommendations for safer, more effective drug regimens. Together, these solutions directly address polypharmacy and the potential for adverse drug events - a leading cause of death in the United States. GalenusRx’s deep data analysis also enhances the quality, safety, and efficiency of virtual clinical trials, allowing for biosimulations based on real patient data that don’t expose patients to risk. The benefits span from consumers to healthcare providers, insurers, and pharmaceutical companies, with GalenusRx’s technology leading the way toward better health outcomes and lower medical costs.

Silo Pharma, Inc. is a developmental stage biopharmaceutical company. The Company specializes in developing novel therapeutics that address underserved conditions including PTSD, stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. Silo Pharma operates in the United States.

Retension Pharmaceuticals is developing RTN-001, a differentiated, tissue-targeted PDE5 inhibitor that has been optimized for the treatment of uncontrolled hypertension. RTN-001 has been evaluated in over 265 subjects across 9 clinical trials. In these studies, RTN-001 was well tolerated and demonstrated a sustained and clinically significant impact on central and brachial blood pressure in patients with uncontrolled hypertension. RTN-001 is a second generation PDE5i that preferentially distributes to cardiovascular tissues, where it acts to mediate a sustained and clinically significant impact on central and brachial blood pressure in patients with uncontrolled hypertension.

RayThera focuses on creating innovative small molecule therapies, particularly in the field of immunology, addressing critical unmet medical needs. The company utilizes decades of drug discovery expertise to enhance the development process while upholding stringent standards.

Taxa is a synthetic microbiome company sculpting the skin microbiome using genetic engineering technologies such as CRISPR/spCas9.

Sealonix focuses on the development and commercialization of hemostatic sealants using its proprietary biomaterials. Sealonix is working on a sealant patch that will provide quick hemostasis for abdominopelvic and orthopedic operations. The PramStat patch is intended to bioabsorb within one week of implantation.

Bio Usawa is a biotechnology company that develops monoclonal antibodies for cancer, ophthalmic, and infectious diseases.

NeuroBionics is pioneering the future of precision bioelectronic medicine by inventing the next generation of implanted devices that will seamlessly interface with the human body.

Avenue Biosciences is pioneering the future of biotechnology, with a mission to transform the development of protein biologics for healthcare advancements. Our cutting-edge, high-throughput engineering platform transforms the production of protein biologics by enabling the simultaneous optimization of critical elements. This breakthrough technology enhances production efficiency, accelerates development timelines, and tackles the challenges of producing complex proteins. Our goal is to drive significant progress in the pharmaceutical industry by providing turnkey solutions that streamline production, improve quality, and unlock new therapeutic possibilities. Backed by validated proof of concept and compelling data, Avenue Biosciences is on a journey to transform healthcare and push the boundaries of what’s possible in protein biologics. We're a team of brilliant minds, each an expert in their field, united by a shared mission to make a real impact in a novel area of biotechnology. We are a highly experienced, entrepreneurial minded team with an impressive scientific background, that lives and breathes a casual, committed, and positive culture and spirit. A closer look We revolutionize protein production with our groundbreaking high-throughput engineering platform. This innovative technology significantly enhances overall production efficiency and quality. We optimize the production of natural single-chain proteins, monoclonal antibodies, bispecific antibodies, fusion proteins, mRNA therapies, and vaccines. Additionally, our platform accelerates the drug and vaccine discovery process. Our mission is to accelerate the development of protein expression systems, covering new protein therapeutics, biosimilars, and other protein expression systems within the biotechnology industry. Our engineering platform empowers biotechnology and pharmaceutical industry customers to speed up development timelines and facilitate the production of difficult-to-express proteins.

Advanced Medicine Partners is a biotechnology company that specializes in viral vector manufacturing for genes and cells.

Primrose Bio is a biotech company that focuses on discovery, development, and manufacturing of new molecules. innovative therapeutics, vaccines and ingredients to aevance global health.

Peregrine Health is a healthcare company formed by Integrative Life Network (ILN) and Integrative Health Centers.

Shinobi Therapeutics focuses on creating hypoimmune CD8αβ iPS-T cells that work with the immune system to treat cancer and other diseases. The company utilizes advanced immune evasion technology to enhance the effectiveness and accessibility of cell therapies. Shinobi's innovative approach aims to reduce costs and improve patient outcomes through durable responses and redosing capabilities.

Spyre Therapeutics combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for inflammatory bowel disease.

TwoStep Therapeutics is developing novel tumor-targeting therapeutics for solid tumors.

Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients' treatment.

Forest Neurotech to empower individuals and improving lives by developing a minimally invasive ultrasonic whole-brain computer interface.

Architect Therapeutics is a developer of therapeutics that focuses on creating treatments for diseases, particularly in the field of cancer.

ParcelBio is a company that creating a programmable method for safely and precisely delivering mRNA to many cell types in the body.

Biostate AI develops generative AI that benefit all human health.

CrossBridge Bio operates as a biotechnology company, innovates ADC therapeutics through stable dual linker payload technology.

Pi Health is a provider of platforms to assist oncology-related clinical trials with identifying sites and helping sponsors manage sites

Mach5 Therapeutics is a biotechnology company.

VIAN Therapeutics is a visionary virtual pharma startup at the forefront of combating microvascular retinal diseases. Focused on conditions like diabetic retinopathy and age-related macular degeneration, we're pioneering a novel solution: VIAN-c4551, a groundbreaking cyclic peptide drug delivered via convenient eyedrop administration. By swiftly stabilizing retinal blood vessels, our non-invasive approach aims to halt vision deterioration earlier than traditional methods (e.g., intraocular injections). With millions affected, VIAN Therapeutics aims to redefine ocular care, offering hope for clearer sight and a brighter future of retinal health.

Doron Therapeutics is a clinical-stage biotechnology company that has developed intra-articular biologic drugs derived from placental tissue and consistently delivers a host of beneficial growth factors with potent anti-inflammatory, tissue-protective, and regenerative capabilities pivotal to the progressive and degenerative disease of osteoarthritis.

Long Description: Aiolos Bio is a biotech company focused on developing therapies for respiratory diseases like asthma as well as other immune conditions. The company is initially focused on advancing AIO-001, a monoclonal antibody therapy for moderate-to-severe asthma that only requires dosing every 6 months. Aiolos Bio was founded by an accomplished team with decades of drug development experience and leadership in the biotech industry.

Amplifyer Bio is a biotechnology research company that develops technology of transformative potential for the liquid biopsy field.

Beacon Therapeutics is an ophthalmic gene therapy company that restores and improves vision and rare retinal diseases that result in blindness.

Vector Biomed is a state-of-the-art custom vector design and GMP manufacturing company. It is a source for safe, high-quality, reliably-manufactured Lentiviral vectors that are critical for producing gene medicines like CAR-T cell therapies and Stem Cell gene therapies.

Crop Diagnostix is a biotechnology company that uses RNA sequencing and AI for predictive agriculture.

Kardigan is a patient-driven heart health firm that is revolutionizing cardiovascular drug development to produce medicines that take patients from symptom management to functional cures.

Speeding lifesaving cures with AI-driven design & real-time insights for faster, intuitive clinical development & patient access.

Junevity is a biotech rewinding complex metabolic disease. Based on 6 years of breakthrough research at UCSF, Junevity's REWIND platform identifies high-level regulators of metabolic disease with known pharmacological pathways. Junevity is advancing multiple therapeutic programs towards a new era of medicines.

Infinity Bio is a Circulating Antibody Repertoire Profiling service company, leveraging a novel technology, MIPSA (Molecular Indexing of Proteins (or Peptides) by Self Assembly) developed by Dr. H. Ben Larman, a pioneer in this field. Our various antigen libraries provide cost effective, comprehensive and quantitative analyses of antibody responses to infections, vaccinations, self-antigens and allergens. Our proprietary method allows for the rapid and flexible content customization. Infinity Bio can design and create customer specific peptide libraries against any target of choice.

Biogenesis is building the end-to-end platform for clinical research.

DANNCE is a deep learning solution to automate behavioral analysis for drug development and disease diagnosis​. Our platform takes patient video as input and uses our proprietary 3-D pose tracking and behavioral analysis algorithms to quantify behavior. DANNCE will help clinicians see the unseeable and drug developers generate real world evidence by using movement data and computer vision.

Avenacy is a rapidly growing U.S.-based specialty pharmaceutical company focused on providing critical injectable medications used to treat patients in various medically supervised settings, from acute care hospitals to outpatient clinics and physician offices. Through a rigorous and optimized selection process, the Company is building out a pipeline of high-quality FDA approved injectable products to ensure a resilient portfolio that can meet the needs of today’s dynamic drug supply chain. With an experienced team, commitment to quality and reliability, and product offerings intended to facilitate safe and efficient patient care, Avenacy strives to be a trusted partner for essential injectable medications.

Eris Biotech is a biotech company that developing hypoxia-activated prodrugs (HAPs) for the treatment of solid tumors.

Sidewinder Therapeutics develops bispecific antibody-drug conjugates (ADCs) aimed at treating solid tumors. Their mission is to create life-saving therapies through precision therapeutics.

Stem Cell Implants is a biotech business that uses stem cell technology to transform dental and craniofacial prosthetic implants. Stem Cell Implants envisions a new regenerative medicine frontier in dentistry.

We are Montara Therapeutics, a San Francisco-based precision-medicine neuroscience biotech startup. Our team boasts significant experience from successful biotech firms such as Mitokinin, Denali, and Soteria, supported by a world-class Scientific Advisory Board (SAB). We bring a new approach to tackling challenging established targets, along with unique experience in developing enzyme activators and domain expertise in mitophagy. Our mission is to create innovative therapies for diseases of the CNS, with a focus on precision medicine and genetically validated targets to enhance drug safety and efficacy.

San Diego based biotechnology company creating novel solutions to combat the problem of drink-spiking and drug-facilitated sexual assault

Caladan Bio specializes in next-generation bioreactors, offering modular, affordable, and cutting-edge solutions.

Brightstar Therapeutics is a biotechnology company focused on innovative treatment options that improve clinical outcomes and quality of life for people living with corneal and ocular surface diseases.

SynsoryBio is a biotechnology research company that offers next-generation protein therapeutics services.

Atommap is a physics-based and ML-augmented computational drug discovery platform

We know that drug development is both an art and a science. The work we do is incredibly technical, intentional, and specific, but there is an art to it - because we must leave room for creativity, innovation and spontaneity. Murals are paintings that transform overlooked or unused spaces - creating something impactful and meaningful. There remains many overlooked opportunities in cancer drug development. This is what inspires us. Our mission is simple, to create novel immunotherapies that can change patients’ lives so they can get back to what matters most - living. Mural Oncology is leveraging its industry-leading protein engineering platform to revolutionize cytokine-based immunotherapies for the treatment of cancer. Immunotherapies have been transformative for some people living with cancer, but unfortunately many patients still do not benefit - either because they are ineligible for treatment or they do not respond well to current therapies. We leverage our expertise in cytokine biology, immune cell modulation and our protein engineering capabilities to develop first and novel immunotherapies. Our goal is to deliver meaningful, clinical benefit across a wide range of cancers, including tumor types where immunotherapies have previously not been effective. Mural Oncology is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers. (NASDAQ: MURA)

Granza Bio is a company that developing cancer therapies based on human body's immune system.

Ti sento means “I hear you" in Italian. At Tisento Therapeutics, we believe that meaningful innovation requires understanding the problem, and that starts with listening. First and foremost, we listen to those impacted by debilitating diseases to understand the daily challenges they face. We also listen to healthcare providers, patient advocates, regulatory agencies, and scientific data. All these inputs inform our thinking and shape how we conduct our research, design our trials, and evolve our company. We are on a mission to deliver medicines that address what matters most. Our lead candidate is zagociguat (formerly CY6463), a Phase 2, first-in-class, brain-penetrant sGC stimulator, which is advancing in MELAS and other genetic mitochondrial diseases. Zagociguat is ideally suited to treat mitochondrial diseases with both CNS and peripheral symptoms, such as cognitive impairment, fatigue, and muscle weakness.

Nanograb is a computational drug discovery company that uses AI to generate the best combination of binders to treat different diseases.

Predicta Biosciences is a precision oncology firm that integrates multiomics and liquid biopsies to create diagnostic tools and therapies. They also have an in-house pipeline for novel immunotherapy targets in pre-clinical stages.

Edgewood Oncology is a clinical-stage biotechnology business established to fulfill the potential of BTX-A51 for patients with solid tumors that are genetically specified and hematologic malignancies. Our goal is to create a novel treatment that will prolong and enhance the lives of those with the greatest unmet medical needs.

Velorum Therapeutics produces powerful cancer treatments that starve tumors.

Via Scientific to help scientists and bioinformaticians generate novel science that improves the world. It was founded in 2022.

Superluminal Medicines is a Boston-based generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created. Our platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure. The predict-design-test architecture accurately models protein shapes and designs highly selective compounds to target the precise structural change for therapeutic effect. Our discovery engine is powered by an industry-leading, pharmacokinetic and toxicology in silico prediction capability. With a lead program candidate expected in the near term, our proprietary pipeline validates our platform with initial programs focused on high-value GPCR targets. We’re pleased to be backed by a strong network of investors including RA Capital Management, Insight Partners, NVIDIA and Gaingels.

Bluestem Biosciences, Inc., is designing biology with the end in mind, to enable existing infrastructure in the Midwest for industrialized synthetic biology. We are leveraging digital biology to facilitate the discovery of biomanufacturing, focused on the sustainable production of chemicals and materials. Bluestem Biosciences was Co-Founder by Billy Hagstrom & Tyler Autera in January 2022. Bluestem is based in Omaha, Nebraska SUSTAINABLE CHEMICALS CREATED FROM ORGANISMS, NOT OIL